Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes

(MedPage Today) — CHICAGO — A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found.
In QWINT-1, there was a similar HbA1c reduction with…

Source link : https://www.medpagetoday.com/meetingcoverage/ada/116189

Author :

Publish date : 2025-06-22 19:56:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes

Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

‘5 Years, 10 Years at Most, I’m Going to Retire’: What We Heard This Week

Related Posts

Postpone ACIP Meeting or Reject Its Conclusions, Sen. Cassidy Says

Political Staff Will Make CDC Great Again, Kennedy Says

CDC Taps Vaccine Skeptic to Lead COVID Shot Review: Here’s What to Know

Medical Debt Follows Cancer Patients Years After Diagnosis

Managing Pregnancy in IBD; Hypertension and MASLD; Nixing Race in HCC Surveillance

Departing CDC Officials Say Monarez’s Firing Was the Final Straw

Postpone ACIP Meeting or Reject Its Conclusions, Sen. Cassidy Says

Political Staff Will Make CDC Great Again, Kennedy Says

CDC Taps Vaccine Skeptic to Lead COVID Shot Review: Here’s What to Know

Medical Debt Follows Cancer Patients Years After Diagnosis

Managing Pregnancy in IBD; Hypertension and MASLD; Nixing Race in HCC Surveillance

Departing CDC Officials Say Monarez’s Firing Was the Final Straw

First Generic GLP-1 Injection OK’d for Weight Loss

Can a Keto Diet be the GLP-1 of Psychiatry?

Categories

Archives